Tigecycline: An investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms

Clinical Therapeutics

Volumn 27, Issue 1, 2005, Pages 12-22

  Garrison, Mark W ^a   Neumiller, Joshua J ^a   Setter, Stephen M ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Visiting Nurses Association   (United States)

Author keywords

Efficacy; GAR 936; Glycylcycline; Gram positive resistance; Pharmacology; Safety; Tigecycline

Indexed keywords

DAPTOMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ABDOMINAL INFECTION; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENTEROCOCCUS; FEVER; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; LIVER FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA AND VOMITING; NONHUMAN; PAIN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; UREA NITROGEN BLOOD LEVEL;

EID: 14844295496     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.01.007     Document Type: Review

References (53)

1. Doem G.V., Heilmann K.P., and Huynh H.K. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison ofresistance rates since 1994-1995 Antimicrob Agents Chemother 45 2001 1721 1729
2. Lowy F.D. Staphylococcus oureus infections N Engl J Med 339 1998 520 532
3. Chopra I. New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors Drug Resist Updat 5 2002 119 125
4. Projan S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent Pharmacotherapy 20 2000 219S 223S
5. Chopra I. Glycylcyclines: Third-generation tetracycline antibiotics Curr Opin Pharmacol 1 2001 464 469
6. Tally F.T., Ellestad G.A., and Testa R.T. Glycylcyclines: A new generation of tetracyclines J Antimicrob Chemother 35 1995 449 452
7. Bergeron J., Ammirati M., and Danley D. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection Antimicrob Agents Chemother 40 1996 2226 2228
8. Zhanel G.G., Homenuik K., and Nichol K. The glycylcyclines: A comparative review with the tetracyclines Drugs 64 2004 63 88
9. Tuckman M., Petersen P.J., and Projan S.J. Mutations in the interdomain loop region of the teLA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines Microb Drug Resist 6 2000 277 282
10. Vasalli M.A., Murphy E., Projan S.J., and Bradford P.A. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis Antimicrob Agents Chemother 47 2003 665 669
11. Dean C.R., Visalli M.A., and Projan S.J. Efflux-mediated resistance to tigecycline (GAR 936) in Pseudomonas aeruginosa PAO1 Antimicrob Agents Chemother 47 2003 972 978
12. Hirata T., Saito A., and Nishino K. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936) Antimicrob Agents Chemother 48 2004 2179 2184
13. San Francisco, Calif Muralidharan G., Getsy J., and Mayer P. Pharmacokinetics (PK), safety and tolerability of GAR 936, a novel glycylcycline antibiotic, in healthy subjects Abstract F-416 Program and abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 26-29, 1999;
14. San Diego, Calif Sesoko S., Umemura K., and Nakashima M. Pharmacokinetics (PK), safety and tolerability of tigecycline (GAR-936) in healthy Japanese males Abstract A-1403 Program and abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30, 2002;
15. Postier R.G., Green S.L., Klein S.R. Tigecycline 200 Study Group Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tige cycline for complicated skin and skin-structureinfections in hospitalized patients Clin Ther. 26 2004 704 714
16. Chicago, III, Abstract A-22 Troy S.M., Muralidharan G., and Micalizzi M. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, 2003
17. Toronto, Canada, Abstract A-502 Muralidharan G., Mojaverian P., and Micalizzi M. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline anti biotic, in healthy subjects Program and abstracts of the 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2000
18. van Ogtrop M.L., Andes D., and Stamstad T.J. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram positive and gram-negative bacteria Antimicrob Agents Chemother 44 2000 943 949
19. Toronto, Canada, Abstract A-2256 Lefort A., Massias L., and Saleh-Mghir A. Pharmacodynamics of Gar-936 (GAR) in experimental endocarditis due to Van-A-type Enterococcus faecium Program and abstracts of the 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2000
20. Biedenbach D.J., Beach M.L., and Jones R.N. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive bloodstream infection isolates and strains producingextended-spectrum beta-lactamases Diagn Microbiol Infect Dis 40 2001 173 177
21. Goldstein E.J., Citron D.M., and Merriam C.V. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens Antimicrob Agents Chemother 44 2000 2747 2751
22. Kitzis M.D., Ly A., and Goldstein F.W. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae Antimicrob Agents Chemother 48 2004 366 367
23. Boucher H.W., Wennersten C.B., and Eliopoulos G.M. In vitro activity of the glycylcycline GAR-936 against gram-positive bacteria Antimicrob Agents Chemother 44 2000 2225 2229
24. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the newglycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 2000 19 36
25. Low D.E., Kreiswirth B.N., Weiss K., and Willey B.M. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus Int J Antimicrob Agents 20 2002 220 222
26. Milatovic D., Schmitz F.J., Verhoef J., and Fluit A.C. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
27. Petersen P.J., Bradford P.A., and Weiss W.J. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens Antimicrob Agents Chemother 46 2002 2595 2601
28. Petersen P.J., Jacobus N.V., and Weiss W.J. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
29. Patel R., Rouse M.S., Piper K.E., and Steckelberg J.M. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistantStreptococcus pneumoniae Diagn Microbiol Infect Dis 38 2000 177 179
30. Betriu C., Rodriguez-Avial I., Sanchez B.A. Spanish Group of Tigecycline In vitro activities of tige cycline (GAR-936) against recently isolated clinical bacteria in Spain Antimicrob Agents Chemother 46 2002 892 895
31. Labthavikul P., Petersen P.J., and Bradford P.A. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model Antimicrob Agents Chemother 47 2003 3967 3969
32. Cercenado E., Cercenado S., Gomez J.A., and Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcy cline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides J Antimicrob Chemother 52 2003 138 139
33. Hoellman D.B., Pankuch G.A., Jacobs M.R., and Appelbaum P.C. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillinsusceptible and -resistant pneumococci Antimicrob Agents Chemother 44 2000 1085 1088
34. [published correction appears in Antimicrob Agents Chemother. 2003;47:2716] Zhanel G.G., Palatnick L., and Nichol K.A. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrob Agents Chemother 47 2003 1867 1874
35. Betriu C., Culebras E., and Rodriguez-Avial I. In vitro activities of tigecycline against erythromycin resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of macrolide and tetracycline resistance Antimicrob Agents Chemother 48 2004 323 325
36. Chicago, III, Abstract E-524 Heine H.S., Dicks R., and Andrews G. In vitro activity of oritavancin (LY33328), levofloxacin, meropenem, GAR936, and linezolid against strains of Bacillus anthracis Program and abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19, 2001
37. Henwood C.J., Gatward T., and Warner M. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) J Antimicrob Chemother 49 2002 479 487
38. Cercenado E., Cercenado S., and Bouza E. In vitro activities of tigecycline (GAR-936) and 12 other antimicro bial agents against 90 Eikenella corrodens clinical isolates Antimicrob Agents Chemother 47 2003 2644 2645
39. Zhanel G.G., Palatnick L., Nichol K.A. CROSS Study Group Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrob Agents Chemother 47 2003 1875 1881
40. Betriu C., Rodriguez-Avial I., and Sanchez B.A. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia J Antimicrob Chemother 50 2002 758 759
41. Jacobus N.V., McDermott L.A., Ruthazer R., and Snydman D.R. In vitro activities of tigecycline against the Bacteroides fragilis group Antimicrob Agents Chemother 48 2004 1034 1036
42. Roblin P.M., and Hammerschlag M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis Int J Antimicrob Agents 16 2000 61 63
43. Edelstein P.H., Weiss W.J., and Edelstein M.A.C. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia Antimicrob Agents Chemother 47 2003 533 540
44. Kenny G.E., and Cartwright F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin,gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones Antimicrob Agents Chemother 45 2001 2604 2608
45. Deshpande L.M., Gales A.C., and Jones R.N. GAR-936 (9-t- butylglycylamidominocycline) susceptibility test development forstreptococci, Haemophilus infuenzae and Neisseria gonorrhoeae:Preliminary guidelines and interpretive criteria Int J Antimicrob Agents 18 2001 29 35
46. Jones R.N. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936 Diagn Microbiol Infect Dis 35 1999 249 252
47. Mercier R.C., Kennedy C., and Meadows C. Antimicrobial activity tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination Pharmacotherapy 22 2002 1517 1523
48. Wallace R.J. Jr., Brown-Elliott B.A., and Crist C.J. Comparison of the in vitro activity of the glycylcycline tige cycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycyclineagainst isolates of nontuberculous mycobacterium Antimicrob Agents Chemother 46 2002 3164 3167
49. Nannini E.C., Pai S.R., Singh K.V., and Murray B.E. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model Antimicrob Agents Chemother 47 2003 529 532
50. San Francisco, Calif, Abstract F-414 Mikels S.M., Brown A.S., and Breden L. In vivo activities of GAR-936 (GAR), gentamicin (GEN), piperacillin (PIP), alone and in combination in a murine model of Pseudomonas aeruginosapneumonia Program and abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 26-29, 1999
51. Murphy T.M., Deitz J.M., and Petersen P.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis Antimicrob Agents Chemother 44 2000 3022 3027
52. Lefort A., Lafaurie M., and Massias L. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis Antimicrob Agents Chemother 47 2003 216 222
53. Chicago, III, Abstract L-739 Murray J., Wilson S., and Klein S. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, 2003